Amgen Oncology is testing the investigational drug tarlatamab (AMG 757) to see if it can help patients with either of two kinds of neuroendocrine cancer: small cell lung cancer (SCLC) or neuroendocrine prostate cancer (NEPC).

Move your cursor to either side of the page to learn more about tarlatamab clinical studies.

Underlined terms can be clicked for definition.

DeLLphi-301: PHASE 2 CLINICAL STUDY

Small Cell
Lung Cancer

A clinical study for patients whose cancer has returned or is not responding to treatment after trying two or more previous treatments.

 

Eligibility & Study Information

Study Information Click to Expand
DISEASE

Small cell
lung cancer (SCLC)

Disease Education

STUDY PHASE

Phase 2

Common Questions

TREATMENT

tarlatamab infusion

About Tarlatamab

DeLLpro-300: PHASE 1B CLINICAL STUDY

Neuroendocrine Prostate Cancer

A clinical study for patients with neuroendocrine prostate cancer (NEPC) that has spread to another site in the body after one previous treatment.

How do I know if I have neuroendocrine prostate cancer?

Eligibility & Study Information

Study Information Click to Expand
DISEASE

Neuroendocrine
prostate cancer (NEPC)

Disease Education

STUDY PHASE

Phase 1B

Common Questions

TREATMENT

tarlatamab infusion

About Tarlatamab